NCT06787339View on ClinicalTrials.gov

Capecitabine in Low Risk Triple Negative Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

January 31, 2030

Conditions
Breast Cancer
Interventions
DRUG

Capecitabine

Capecitabine 650mg/m2, bid, p.o for 1 year

Trial Locations (1)

Unknown

breast cancer institute of Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER